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Abstract
The current standard of care for hepatitis C virus (HCV) infection – combination therapy with pegylated interferon and
ribavirin – elicits sustained responses in only ,50% of the patients treated. No alternatives exist for patients who do not
respond to combination therapy. Addition of ribavirin substantially improves response rates to interferon and lowers
relapse rates following the cessation of therapy, suggesting that increasing ribavirin exposure may further improve
treatment response. A key limitation, however, is the toxic side-effect of ribavirin, hemolytic anemia, which often
necessitates a reduction of ribavirin dosage and compromises treatment response. Maximizing treatment response thus
requires striking a balance between the antiviral and hemolytic activities of ribavirin. Current models of viral kinetics
describe the enhancement of treatment response due to ribavirin. Ribavirin-induced anemia, however, remains poorly
understood and precludes rational optimization of combination therapy. Here, we develop a new mathematical model of
the population dynamics of erythrocytes that quantitatively describes ribavirin-induced anemia in HCV patients. Based on
the assumption that ribavirin accumulation decreases erythrocyte lifespan in a dose-dependent manner, model predictions
capture several independent experimental observations of the accumulation of ribavirin in erythrocytes and the resulting
decline of hemoglobin in HCV patients undergoing combination therapy, estimate the reduced erythrocyte lifespan during
therapy, and describe inter-patient variations in the severity of ribavirin-induced anemia. Further, model predictions
estimate the threshold ribavirin exposure beyond which anemia becomes intolerable and suggest guidelines for the usage
of growth hormones, such as erythropoietin, that stimulate erythrocyte production and avert the reduction of ribavirin
dosage, thereby improving treatment response. Our model thus facilitates, in conjunction with models of viral kinetics, the
rational identification of treatment protocols that maximize treatment response while curtailing side effects.
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Introduction
130–170 million people worldwide are currently infected with
hepatitis C virus (HCV) [1]. Over 70% of HCV infections become
chronic and if untreated may lead to cirrhosis and hepatocellular
carcinoma, necessitating liver transplantation [1]. The standard of
care for HCV infection involves combination therapy with
pegylated interferon and ribavirin [2]. Ribavirin alone does not
elicit a lasting antiviral response [3–6], yet it substantially improves
treatment response in combination with interferon [7–11]. For
instance, whereas ,29% of the patients treated with interferon
exhibited a sustained virological response (SVR), the response rate
increased to ,56% upon addition of ribavirin [8]. Ribavirin,
however, is associated with the side-effect, hemolytic anemia,
which often renders therapy intolerable [4,12–15]. With the
standard ribavirin dosage of 1000–1200 mg/day, 54% of the
patients treated experienced a decline in the hemoglobin (Hb) level
of over 3 g/dL, and 10% of the men and 7% of the women treated
experienced an Hb decline of over 5 g/dL (normal Hb range: 14–
16 g/dL) [15]. This drop in Hb often necessitates a reduction of
ribavirin dosage, which significantly compromises treatment
response [7,13,14,16]. The probability of achieving SVR is
estimated to decrease from ,65% to ,45% when ribavirin
dosage is reduced from ,15 mg/kg to ,7 mg/kg of body weight,
in combination with pegylated interferon at 1.5 mg/kg of body
weight [7]. Patients receiving fewer than 60% of the planned
ribavirin doses had lower response rates [14], indicating that lower
cumulative ribavirin exposure results in poorer treatment response
[13,16]. The rates of relapse of infection following the end of
treatment also increased upon lowering ribavirin dosage [14,16].
In a recent clinical trial where interferon was employed with
telaprevir, a promising new inhibitor of HCV protease, response
rates were lowest in patients who were not administered ribavirin
[17], underscoring the importance of ribavirin in achieving SVR.
Alternatives for patients who do not respond to combination
therapy do not exist yet [2,18]. Significant efforts are underway
therefore to identify treatment protocols that maximize response
rates to combination therapy while curtailing side-effects [16,19–
25]. A particularly promising strategy is to supplement combina-
tion therapy with growth hormones, such as erythropoietin, that
stimulate erythropoiesis and thus avert the reduction of ribavirin
dosage, potentially improving treatment response [26–31]. The
predominant mechanism(s) of the anti-HCV activity of ribavirin
remain to be established [32–34]. Mathematical models of viral
kinetics have been developed that describe the antiviral activity of
interferon and the enhancement of treatment response rates due to
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antiviral drugs [34–42]. Ribavirin-induced anemia, on the other
hand, remains poorly understood [13,24,25,43–47] and precludes
rational optimization of combination therapy.
Here, we construct a mathematical model of the population
dynamics of erythrocytes that quantitatively describes ribavirin-
induced anemia and informs future strategies for improving
outcomes of combination therapy. Model predictions capture
experimental observations of the accumulation of ribavirin in
erythrocytes and the ensuing Hb decline in HCV patients
following the onset of combination therapy, estimate the enhanced
turnover rate of erythrocytes during therapy and the threshold
ribavirin exposure beyond which anemia is intolerable, present
guidelines for the optimal usage of growth hormone supplements,
and provide a framework, in conjunction with models of viral
kinetics, for rational optimization of combination therapy.
Results
Model formulation
Prior to the onset of treatment with ribavirin, the population of
erythrocytes (RBCs) in an HCV infected individual is constant; a
balance exists between RBC production and death (Fig. 1).
Following the onset of treatment, ribavirin administered orally gets
rapidly transported from the plasma to RBCs, where it is
phosphorylated to its mono-, di- and tri-phosphate analogs
(RMP, RDP, and RTP) [48]. Phosphorylated analogs are neither
easily metabolized nor transported out of RBCs [48]. Conse-
quently, ribavirin accumulates inside RBCs in the form of its
phosphorylated analogs; the total intracellular concentration of
ribavirin can be .100-fold its extracellular concentration [47].
This dramatic accumulation of ribavirin may induce oxidative
damage and result in enhanced extra vascular death of RBCs [12].
Indeed, RBC lifespan decreased from 107622 d in HCV patients
not exposed to ribavirin to 39613 d in HCV patients undergoing
treatment with ribavirin [49,50]. The shortened RBC lifespan
creates an imbalance between RBC production and death and
results in a decline in the RBC population. Accordingly, Hb levels
drop and patients become anemic. We construct a mathematical
model to describe this dynamics of ribavirin-induced anemia
(Methods).
Model predictions
Population dynamics of RBCs during treatment with
ribavirin. We present model predictions in terms of the
cumulative population, m(C,t), which is the population of RBCs
at time t following the onset of treatment in which the
concentration of ribavirin phosphorylated analogs, RXP, is less
than or equal to C (Fig. 2A). (RXP comprises RMP, RDP, and
RTP.) At the start of treatment (t~0), no cells contain RXP, and
m(C,0)~N0 for all C, where N0 is the steady population of RBCs
prior to the onset of treatment. In other words, the population of
cells carrying RXP at concentrations smaller than or equal to C is
N0 for all C§0.A tt~0, the production and death rates of RBCs
are in balance (Fig. 2B), the hemoglobin level, Hb=Hb0, and the
average intracellular concentration of ribavirin, Cavg~0 (Fig. 2C).
With time, ribavirin accumulates inside cells. At any time tw0,a
distribution of RXP concentrations across cells emerges with cells
exposed to ribavirin longer possessing higher concentrations of
RXP. Thus, cells present from the start of treatment possess the
highest concentration of RXP. At t~1 d, for instance, the latter
cells possess RXP at the concentration C&0:04Cmax, where
Cmax=kpCmax
p =kd is the maximum intracellular concentration of
Figure 1. Schematic of the population dynamics of RBCs in
HCV infected individuals. A, Before the onset of combination
therapy, the production and death rates of RBCs are balanced and the
population of RBCs in plasma is constant. B, Following the onset of
therapy, ribavirin enters RBCs and increases their death rates. Cells born
at different times are exposed to ribavirin for different durations and
hence carry different concentrations of ribavirin. The enhanced death
rate lowers the RBC population, which triggers an increase in the RBC
production from the bone marrow by a negative feedback through the
hormone erythropoietin.
doi:10.1371/journal.pcbi.1001072.g001
Author Summary
The treatment of HCV infection poses a major global
health-care challenge today. The current standard of care,
combination therapy with interferon and ribavirin, works
in only about half of the patients treated. Because no
alternatives are available yet for patients in whom
combination therapy fails, identifying ways to improve
response to combination therapy is critical. Increasing
exposure to ribavirin does improve response but is
associated with the severe side-effect, anemia. One way
to maximize treatment response therefore is to increase
ribavirin exposure to levels just below where anemia
becomes intolerable. A second way is to supplement
combination therapy with growth hormones, such as
erythropoietin, that increase the production of red blood
cells (erythrocytes) and compensate for ribavirin-induced
anemia. Rational optimization of combination therapy thus
relies on a quantitative description of ribavirin-induced
anemia, which is currently lacking. Here, we develop a
model of the population dynamics of erythrocytes in
individuals exposed to ribavirin that quantitatively de-
scribes ribavirin-induced anemia. Model predictions cap-
ture several independent observations of ribavirin-induced
anemia in HCV patients undergoing combination therapy,
estimate the threshold ribavirin exposure beyond which
anemia becomes intolerable, suggest guidelines for the
usage of growth hormones, and facilitate rational optimi-
zation of therapy.
Ribavirin-Induced Anemia
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p
(Fig. 2A). Cells born after the onset of treatment possess RXP at
concentrations smaller than &0:04Cmax at t~1 d. Because most
of the cells present at t~1 d are from the population that existed
at the start of therapy, m(C,t) exhibits a sharp rise at
C&0:04Cmax and reaches the value N(t=1) (Fig. 2A). With
time, the sharp rise in m(C,t) shifts to higher values of C (Fig. 2A)
indicating greater accumulation of RXP. Accordingly, Cavg
increases (Fig. 2C). Cells die at increasing rates as intracellular
RXP accumulates (Fig. 2B). The population of RBCs, N(t), and,
hence, Hb correspondingly decrease (Fig. 2C). New cells are
continuously produced at a rate that increases as the RBC
population declines (Fig. 2B). Eventually, a new balance between
RBC production and death is attained, m(C,t) reaches a steady
distribution, Cavg reaches an asymptotic maximum C?
avg, and Hb
attains a new, lower steady value Hb?.
Factors that influence the severity of ribavirin-induced
anemia. An increase in the steady state plasma concentration of
ribavirin, Cmax
p , which may be achieved with a higher dosage,
results in an increase in C?
avg and a decrease in Hb?, illustrating
the more severe anemia that results with increased ribavirin
exposure. For instance, increasing Cmax
p from 5 mMt o1 5mM
increases the total drop in Hb, DHb~Hb0{Hb?, from ,2 g/dL
to ,5 g/dL (Fig. 3A). An increase in the intracellular phos-
phorylation rate, kp, (or a decrease in the loss rate of intracellular
RXP, kd) results in a higher C?
avg for the same Cmax
p , which in turn
elevates cell death rates and lowers Hb?. Thus, DHb increases
from ,2.5 g/dL when kp~50 d
21 to ,3.5 g/dL when kp~80
d
21 (Fig. 3B), illustrating that differences in the intracellular
metabolism of ribavirin may contribute to inter-patient variations
in the severity of ribavirin-induced anemia. Enhancing the RBC
production rate, by increasing Pmax (see Eq. (3)), (or lowering the
sensitivity of the RBC death rate to ribavirin accumulation, by
increasing C50 or decreasing c (see Eq. (2))), reduces DHb (Fig. 3C).
Administration of growth hormones, such as erythropoietin,
enhances the RBC production rate, which reduces DHb for the
same ribavirin exposure and thus improves the tolerability of
ribavirin. Similarly, decrease in the intracellular inosine
triphosphatase level, observed recently in some patients [51],
may interfere with RTP activity and lower the sensitivity of the
RBC death rate to ribavirin, which also reduces DHb and
improves the tolerability of ribavirin.
Inter-patient variations. Inter-patient variability in the
severity of anemia may arise from variations in the intracellular
uptake, accumulation, or metabolism of ribavirin, as well as in the
dependence of the RBC lifespan on ribavirin accumulation and in
the sensitivity of the RBC production rate to changes in Hb.T o
obtain a measure of this inter-patient variability, we calculated
DHb using 500 different combinations of the values of the
parameters, kp, kd, C50 and c, for a range of values of Cmax
p . The
parameter values for each combination were chosen randomly
from Gaussian distributions based on the mean values and
confidence levels of the respective parameters obtained from
comparisons of our model predictions with patient data (see
below). Indeed, we find that inter-patient variations in DHb may
be substantial for any ribavirin exposure (Fig. 4A) or intracellular
accumulation (Fig. 4B). Further, the variation increases with
increase in ribavirin exposure and intracellular accumulation.
Below, we compare our model predictions with experiments.
Comparisons of model predictions with patient data
We consider a recent study of the time-evolution of Cavg and Hb
in 19 Japanese patients following the onset of combination therapy
[47]. In this latter study, no reduction of ribavirin dosage is
Figure 2. Model predictions of the dynamics of ribavirin-
induced anemia. A, The cumulative population, m(C,t), of RBCs as a
function of the intracellular concentration of RXP, C, at different times, t,
following the onset of combination therapy, predicted by Eqs. (1)–(3).
Parameters employed are listed in Table 1. m(C,t) is normalized by N0
and C by Cmax=kpCmax
p =kd. B, The production rate, P(t), and the death
rate
Ð ?
0
n(C,t)D(C)dC of RBCs. C, The corresponding change in Hb (red)
and Cavg (green).
doi:10.1371/journal.pcbi.1001072.g002
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whether C?
avg,1000 mM (7 patients) or C?
avg.1000 mM (12
patients); the data are reported as the average within each group.
We fit model predictions of Cavg and Hb to the data of the former
7 patients using kp, kd, C50 and c as adjustable parameters.
(Interferon may also induce anemia, but does so to a much smaller
extent than ribavirin [13]. We therefore assume that the Hb
decline in patients undergoing combination therapy is primarily
due to ribavirin.) We fix the remaining parameters based on
previous studies or from analysis of independent experiments
(Methods). Model predictions provide good fits to the data and
yield estimates of kp, kd, C50 and c (Fig. 5A). The fits suggest that
our model is able to describe the underlying dynamics of ribavirin-
induced anemia in HCV patients.
Interestingly, with the same parameter values, our model
captures changes in Hb and Cavg from the other 12 Japanese
patients, as well as an independent data set of Hb decline in
another group of HCV patients undergoing combination therapy
[29] (Fig. 5B), validating our best-fit parameter estimates. Further,
with the same parameter values, we estimate that the RBC lifespan
is 38 days (95% CI: 19–55 days) in Japanese patients with
C?
avg,1000 mM and 33 days (95% CI: 14–53 days) in Japanese
patients with C?
avg.1000 mM. These estimates of the RBC lifespan
are in close agreement with independent estimates, 39613 days,
from measurements of alveolar carbon monoxide [49,50],
presenting another successful test of our model. Finally, we find
that our predictions of the dependence of DHb on Cmax
p and C?
avg
using the same parameters above are also in agreement with
observations in the Japanese patients [47] (Fig. 5C,D). Our model
thus presents a robust description of ribavirin-induced anemia in
HCV patients undergoing combination therapy.
Clinical implications
Our model has several clinical implications. First, it enables
estimation of the threshold ribavirin exposure beyond which
anemia is intolerable. Current treatment guidelines recommend a
reduction of ribavirin dosage when Hb decreases below 10 g/dL.
We apply our model to predict Hb? as a function of Cmax
p .W e
find that on average (when Hb0 =14.4 g/dL) Hb?,10 g/dL
when Cmax
p .13 mM (Fig. 6A). Thus, steady state plasma
concentrations above 13 mM would render ribavirin therapy
intolerable. While the dependence of the peak plasma concentra-
tion on dosage following a single ribavirin dose has been
determined [48], the dependence of Cmax
p on dosage remains to
be established. A description of the multiple dose pharmacokinet-
ics of ribavirin, which also remains elusive [6,34,48,52,53], would
establish the dosage corresponding to Cmax
p of 13 mM that would
render ribavirin intolerable.
Second, when Cmax
p is above the threshold, our model allows
estimation of the increase in RBC production, which may be
achieved by administration of exogenous growth hormones such as
recombinant erythropoietin, necessary to avert the currently
recommended reduction of dosage. Because growth hormones
also have side-effects [29,54], one strategy is to use them at levels
just enough to increase Hb? to 10–12 g/dL (rather than the
pretreatment level), which renders ribavirin tolerable [16]. We
apply our model to predict the level of RBC production necessary
for achieving Hb? of 10–12 g/dL for different values of Cmax
p
(Fig. 6B). Thus, when Cmax
p =15mM, RBC production rates of
8.44 and 10.2 million cells s
21 are necessary for ensuring Hb? of
10 and 12 g/dL, respectively. Increase in endogenous erythropoi-
etin levels during therapy, also observed experimentally [45,55],
results in an enhanced production rate of 8.1 million cells s
21,
which is 3.5-fold higher than the basal production rate (here 2.3
million cells s
21 in the absence of ribavirin) but inadequate to
achieve the desired Hb?. Hormone supplements may be
employed to provide the balance of 0.34 or 2.1 million cells s
21
Figure 3. Factors influencing the dynamics of ribavirin-induced
anemia. Changes in Hb (red) and Cavg (green) predicted by Eqs. (1)–(3)
for different parameter values: A, Cmax
p ~5 mM (solid lines), 10 mM
(dashed lines) and 15 mM (dotted lines). B, kp~50d
{1 (solid lines),
65 d
21 (dashed lines), 80 d
21 (dotted lines). C, Pmax~
5:4|1011 cells d
{1 (solid lines), 8:3|1011 cells d
{1 (dashed lines),
1:1|1012 cells d
{1 (dotted lines). The other parameters are mentioned
in Table 1.
doi:10.1371/journal.pcbi.1001072.g003
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dL, respectively. This deficiency in RBC production that hormone
supplements must compensate increases with ribavirin exposure
(Fig. 6B).
Discussion
The ability to enhance treatment response rates renders
ribavirin central to the treatment of HCV infection. Maximizing
the benefit of ribavirin to patients requires striking the right
balance between its antiviral activity and its treatment-limiting
side-effect, hemolytic anemia. Rational approaches to therapy
optimization thus rely on quantitative descriptions of both the
antiviral and the hemolytic activities of ribavirin. Extant
mathematical models predict the enhancement in treatment
response due to ribavirin [34–42]. Ribavirin-induced anemia,
however, remains poorly described and limits our ability to
maximize treatment response. Here, we fill this gap by
constructing a model of the population dynamics of RBCs that
quantitatively describes ribavirin-induced anemia. By assuming
that intracellular accumulation of ribavirin enhances RBC death
rate in a dose-dependent manner, our model captures several
independent observations of ribavirin-induced anemia in HCV
patients undergoing combination therapy. In particular, our
model predicts the dynamics of the accumulation of ribavirin in
RBCs and the resulting decline of Hb in patients following the
onset of therapy, estimates the reduced lifespan of RBCs during
therapy, and describes inter-patient variations in the severity of
anemia, thus presenting a robust description of ribavirin-induced
anemia, which, in conjunction with models of viral kinetics, may
facilitate identification of treatment protocols that maximize the
impact of ribavirin in the treatment of HCV infection.
Our model has clinical implications. First, it allows estimation of
the threshold ribavirin exposure beyond which ribavirin-induced
anemia becomes intolerable. For instance, with model parameters
that describe ribavirin-induced anemia in the patients we
considered (Fig. 5), we estimate that steady state plasma ribavirin
concentrations above 13 mM would render ribavirin therapy
intolerable. Determining dosage levels corresponding to this steady
state plasma concentration requires knowledge of the pharmaco-
kinetics of ribavirin, which is currently lacking [6,34,48,52,53].
Ribavirin pharmacokinetics is peculiar because of an unusually
long elimination phase that follows rapid absorption and
distribution phases upon oral dosing [48]. Standard absorption-
elimination models of drug pharmacokinetics are unable to
describe this long elimination phase. Models that include
additional compartments have been proposed to capture the
three-phase pharmacokinetics of ribavirin [52], but the biological
origin of these compartments remains unclear. An additional
complication is that the half-life of the elimination phase increases
from 79 h following a single dose to 274–298 h following multiple
dosing [48], suggesting that parameters that describe single dose
pharmacokinetics may not apply to multiple dose pharmacokinet-
ics. In the absence of rigorous models of ribavirin pharmacoki-
netics, one may have to rely on empirical relationships between
the dosage and the resulting steady state plasma concentration
following multiple dosing (e.g., [56]) to establish the dosage that
would ensure tolerability of ribavirin while maximizing treatment
response.
Second, our model suggests guidelines for the usage of hormone
supplements, such as erythropoietin, which enhance RBC
production and improve the tolerability of ribavirin. For instance,
we predict that when ribavirin accumulates to a plasma
concentration of 15 mM, the associated enhanced RBC death
rate elicits a natural response that increases RBC production 3.5-
fold, from 2.3 to 8.1 million cells s
21. This response, however, is
inadequate to suppress ribavirin-induced anemia adequately and
renders ribavirin intolerable. We estimate then that growth
hormone supplements must increase RBC production rate by an
additional 0.34–2.1 million cells s
21 to render ribavirin tolerable.
This compensation that hormone supplements must provide
increases with ribavirin accumulation. Identifying the dosage of
Figure 4. Model predictions of the variations in the severity of ribavirin-induced anemia. The reduction in Hb (DHb~Hb0{Hb?)
predicted by Eqs. (1)–(3) as a function of A, Cmax
p , and B, C?
avg, for 500 different combinations of the parameter values (mean6s.d.)
Cmax
p (7:5+1:9mM), kp(65+8d
{1), kd(0:5+0:07d
{1), C50(408+98mM), and c(1+0:35). The standard deviations on the parameter values
correspond to the 95% confidence limits obtained from the best-fits to patient data (see Fig. 5). The other parameters are mentioned in Table 1.
doi:10.1371/journal.pcbi.1001072.g004
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requires knowledge of the dose-response relationships and of the
pharmacokinetics of the growth hormones, which are yet to be
fully elucidated [26–31].
Third, genetic variations that resulted in a deficiency in the
enzyme inosine triphosphatase (ITPA) were recently found to
protect HCV patients against ribavirin-induced anemia [51].
Deficiency in ITPA causes an increase in inosine triphosphate
levels in RBCs, which is thought to interfere with RTP activity and
thereby suppress the hemolytic potential of ribavirin. Because
deficiency in ITPA is a clinically benign condition, therapeutic
intervention to suppress ITPA presents a promising new strategy
to curtail ribavirin-induced anemia without compromising the
antiviral activity of ribavirin [51]. Our model may be adapted to
inform the development of such an intervention strategy. In our
model, the dependence of the death rate of RBCs on ribavirin
accumulation, determined by Eq. (2) (Methods), would now be a
function of the ITPA level. Thus, experiments that determine how
variations in the ITPA level both in the absence and in the
presence of ribavirin influence RBC lifespan would provide the
Figure 5. Comparisons of model predictions with experiments. A, Best-fits of model predictions (lines) of Hb (red) and Cavg (green) with
experimental data (symbols) from 7 Japanese patients with C?
avg,1000 mM [47]. We let Hb0=14.4 g/dL and Cmax
p ~7:5mM following the mean
reported values for these patients [47]. We use kp, kd, C50, and c as adjustable parameters. The remaining parameters are mentioned in Table 1. The
resulting best-fit parameter estimates (95% CI) are kp~65d
{1(47{84d
{1), kd~0:5d
{1(0:3{0:7d
{1), C50~408mM(189{628mM),a n d
c~1(0:2{1:8). Dashed lines show 95% confidence intervals on the predictions. B, Comparisons of our predictions (lines) of Hb (red) and Cavg
(green) using the parameters above with data (symbols) from 12 Japanese patients with C?
avg.1000 mM (solid circles) [47]. In the latter patients, the
mean Hb0<15 g/dL and Cmax
p ~9:8mM. We also show comparisons with independent data from 20 patients [29] (open circles) with mean
Hb0=15.1 g/dL. Solid lines are predictions with Hb0=15.1 g/dL and Cmax
p ~9:8mM, and the mean parameters mentioned above, and dashed lines
represent standard deviations. C, D, Model predictions (lines) and experimental observations (symbols) of the reduction in Hb (DHb~Hb0{Hb?)
under combination therapy as a function of C, Cmax
p , and D, C?
avg, in 19 Japanese patients [47]. Solid lines represent predictions with the mean
parameter values above and dashed lines represent standard deviations obtained from several hundred realizations of our model predictions for
different combinations of the values of kp, kd, C50, and c generated randomly from distributions based on the best-fit parameter estimates and 95%
confidence limits mentioned above.
doi:10.1371/journal.pcbi.1001072.g005
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ITPA in ribavirin-induced anemia. The resulting model would
enable determination of the minimal inhibition of ITPA necessary
to maintain ribavirin-induced anemia within tolerable limits.
Conversely, using information of the ITPA level intrinsic to a
patient, the model can be applied to predict the maximum
ribavirin dosage that the patient can tolerate, thus presenting an
avenue for personalizing the treatment of HCV infection.
Methods
Model development
We consider the RBC population in an individual at time t
following the onset of treatment with ribavirin (t=0) (Fig. 1). RBCs
produced at different times in the interval from 0 to t will have
been exposed to ribavirin for different durations and accordingly
have different intracellular levels of ribavirin. We define n(C,t)DC
as the population of RBCs that contain ribavirin phosphorylated
analogs, RXP, which comprises RMP, RDP, and RTP, at
concentrations between C and CzDC at time t. n(C,t) is thus
the number density of RBCs containing RXP at concentration C
at time t. The time evolution of n(C,t) is governed by the following
equation (Text S1)
L
Lt
n(C,t)~{
L
LC
½Q(C,Cc)n(C,t) {n(C,t)D(C) ð1Þ
The first term on the right-hand-side in Eq. (1) represents the
change in n(C,t) due to intracellular phosphorylation of ribavirin.
Q(C,Cc)~kpCc{kdC is the net rate of increase of C due to
phosphorylation, Cc is the intracellular concentration of (unpho-
sphorylated) ribavirin, kp is the phosphorylation rate and kd is the
rate of loss, including by possible slow dephosphorylation, of RXP. In
vitro studies of ribavirin uptake by RBCs observe rapid (,10 min)
equilibration of intracellular and extracellular ribavirin [53,57]. We
assume therefore that Cc(t)&Cp(t), the concentration of ribavirin in
plasma. With twice daily oral administration of ribavirin, Cp rises
from zero at t~0 and reaches an asymptotic maximum, Cmax
p ,s o
that Cp(t)~Cmax
p (1{exp({t=ta)),w h e r eta is the characteristic
timescale of the accumulation of ribavirin in plasma [6,38].
The second term on the right-hand side of Eq. (1) accounts for
the loss of RBCs due to their death. We assume that the death
rate, D, of RBCs increases with C as follows
D(C)~D0 1z
C
C50
   c   
ð2Þ
where D0 is the death rate of RBCs in the absence of ribavirin, C50
is that value of C at which the death rate doubles (or the lifespan
halves) compared to that in the absence of ribavirin, and c,
analogous to the Hill coefficient, determines the sensitivity of D to
changes in C. (A saturable form for D(C) appears inconsistent with
available data; see Text S2, Fig. S1.)
Equation (1) is constrained by the initial condition that C~0 in
all cells at the start of therapy, so that n(C,0)~N0d(C), where N0
is the population of RBCs at t=0, and d(C) is the Dirac delta
function, which satisfies d(C=0)~0 and
ð ?
{?
d(C)dC~1. In other
words, the Dirac delta function ensures that no cells have RXP at
non-zero concentrations at t=0. A second constraint on Eq. (1) is
imposed by the boundary condition that when t.0, newborn cells
contain no RXP so that n(0,t)~P(t)=Q(0,Cc) (Text S1) where
P(t)~
Pmaxh
b
h
bz
N(t)
V
   b ð3Þ
is the rate of production of RBCs at time t.
The production of RBCs by the bone marrow is regulated by a
negative feedback mechanism involving the hormone erythropoi-
etin [58]. Recent studies on modeling erythropoiesis elucidate the
complexities involved in a quantitative description of this feedback
mechanism [59–65]. Here, we employ Eq. (3) to capture the
essential features of this negative feedback: As the population of
RBCs, N(t)~
ð ?
0
n(C,t)dC, decreases, P increases. Pmax is the
maximum production rate of RBCs, which occurs when N is
Figure 6. Model predictions of threshold ribavirin exposure
and requisite RBC production. A, Prediction of Hb? as a function of
Cmax
p . The arrow indicates the threshold Cmax
p above which Hb?,10 g/
dL. B, Predictions of the RBC production rate during therapy (black) and
the production rate required to maintain Hb? of 10 g/dL (pink) and
12 g/dL (blue) as functions of Cmax
p . The arrows indicate the desired
production rates when Cmax
p ~15mM. Parameter values employed are
mentioned in Table 1.
doi:10.1371/journal.pcbi.1001072.g006
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volume of blood (N=V) at which P~Pmax=2, V is the volume of
blood, and b, analogous to the Hill coefficient, determines the
sensitivity of P to changes in N=V. Eq. (3) provides good fits to
independent measurements of the dynamics of the recovery of
RBCs following phlebotomy (Text S3, Fig. S2).
Equations (1)–(3) present a model of the population dynamics of
RBCs in individuals undergoing treatment with ribavirin. We
solve the equations (see below) and obtain the population density,
n(C,t), and the corresponding cumulative population, m(C,t)~
ð C
0
n(C0,t)dC0, using which we predict the time-evolution of the
hemoglobin level in blood, Hb(t)~
100
3
ve
V
N(t) (where ve is the
volume of a single erythrocyte); the average concentration of
ribavirin in RBCs, Cavg(t)~
1
N(t)
ð ?
0
n(C,t)(CzCc)dC; and the
average RBC lifespan, 1=Davg, where Davg(t)~
1
N(t)
ð ?
0
n(C,t)
D(C)dC is the average death rate of RBCs.
Solution of model equations using the method of
characteristics
Equation (1) along with the initial and boundary conditions is
equivalent to the following set of differential equations obtained
using the method of characteristics (Text S4)
dSi(t)=dt~{D(Ci)Si(t)
Si(ti)~
N0 i~0
P(ti)Dti ~1,2,3,:::
(
dCi(t)=dt~kpCc(t){kdCi(t)
Ci(ti)~0
ð4Þ
where Si(t) is the subpopulation of cells born within an interval Dt of
ti~iDt that survive at time t. Ci(t) is the concentration of RXP in the
latter cells at time t. We solve Eq. (4) along with Eqs. (2) and (3) with
Dt~0:01 d using a program written in MATLAB (Text S5). We
validate our solution methodology against an analytical solution that
can be obtained in the limiting case when the RBC death rate is
independent of RXP accumulation (Text S6, Fig. S3). We also ensure
that Dt~0:01 d allows accurate integration of Eq. (4) without
compromising computational efficiency (Fig. S4). From the solution,
we calculate the quantities of interest, viz., m(C,t)~
P
i[fCiƒCg
Si(t),
N(t)~
P
i
Si(t), Cavg(t)~Cc(t)z
1
N(t)
X
i
Ci(t)Si(t),a n dDavg(t)
~
1
N(t)
X
i
D(Ci(t))Si(t).
Model parameters
We employ the following values of the model parameters unless
stated otherwise. The average RBC lifespan in normal man is
,120 days [49,66], which corresponds to D0~0:0083 d
21. We let
b=7 following earlier studies [59] and obtain Pmax~8:4|1012
cells d
21 from an independent analysis of blood loss experiments
(Text S3). We fix V~5L and ve~9|10{14 L [67]. Using
Hb0~14:4g=dL [47], we get N0~2:4|1013 cells. We obtain h
from the initial steady state P(0)~D0N0. Further, we let
Cmax
p ~7:5mM [47] and because ribavirin accumulates in plasma
to its maximum concentration in ,4 weeks, we set ta~5:4d
[6,38]. The remaining parameter values kp~65d
{1, kd~
0:5d
{1, C50~408mM, and c~1 are obtained from best-fits of
our model predictions to experimental data (Fig. 5A). We
summarize model parameters and their values in Table 1.
Fits of model predictions to patient data
We fit model predictions to experimental data (Fig. 5A) using
the nonlinear regression tool NLINFIT in MATLAB.
Table 1. Summary of model parameters and their values employed.
Parameter Description Value (95% CI)
a Source
V Volume of blood 5 L [67]
ve Volume of one RBC 9610
214 L[ 6 7 ]
ta Characteristic timescale of accumulation of RBV in plasma 5.4 d [6,38]
b Coefficient determining sensitivity of RBC production rate to
changes in number per volume of RBCs
7[ 5 9 ]
D0 Death rate of RBCs in the absence of ribavirin 8.3610
23 d
21 [49,66]
Hb0 Initial Hb level 14.4 g/dL [47]
Cmax
p Steady state plasma RBV concentration 7.5 mM[ 4 7 ]
h RBC population per unit volume at which RBC production
rate is half maximal
Determined from pretreatment
steady state, P(0)~D0N0
Pmax Maximum production rate of RBCs 8.4610
12 cells d
21 Best-fit (Text S3)
kp Phosphorylation rate of ribavirin in RBCs 65 (47–84) d
21 Best-fit (Fig. 5A)
kd Loss rate of ribavirin phosphorylated analogs in RBCs 0.5 (0.3–0.7) d
21 Best-fit (Fig. 5A)
C50 Concentration of ribavirin phosphorylated analogs at which RBC
death rate is twice the pretreatment value
408 (189–628) mM Best-fit (Fig. 5A)
c Coefficient determining sensitivity of RBC death rate to changes
in concentration of ribavirin phosphorylated analogs
1 (0.2–1.8) Best-fit (Fig. 5A)
aTypical values employed. Variations are indicated in the text and in figure legends.
doi:10.1371/journal.pcbi.1001072.t001
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